Improved Synthesis Route for Molnupiravir

Improved Synthesis Route for Molnupiravir

Author: Sarah Maier

Molnupiravir (pictured) is an antiviral drug candidate undergoing clinical trials as a potential treatment for COVID-19. Studies in mice have shown that administration of molnupiravir leads to lower virus titers and suppresses virus transmission. Easy oral applicability and a relatively simple chemical structure allowing for a fast synthesis of molnupiravir are additional benefits.

Molnupiravir can be synthesized from the commercially available nucleoside cytidine in only two steps. This starting material is cheap, abundant, and frequently used in food additives and animal feed. The available synthesis routes are not ideal, however, because they require chromatographic purification, large amounts of solvents, and a high enzyme loading for the enzymatic esterification of the intermediate.

David R. Snead, Medicines For All Institute, Richmond, VA, USA, and colleagues have developed an improved two-step synthesis of molnupiravir from cytidine with an overall yield of 60 %. The first step in the synthesis of molnupiravir from cytidine is the hydroxamination of cytidine with hydroxylamine to give N-hydroxycytidine (NHC). The original yield of the reaction was only 50 % and the reaction required large amounts of solvent and chromatographic purification. Substituting hydroxylamine with hydroxylamine sulfate and using pure water instead of an isopropanol-water mixture solved these problems. NHC was easily purified by crystallization as the hydrate in high purity.

In the second synthesis step, NHC is enzymatically acylated to give the target compound. The previous synthesis required a very high enzyme loading (200 wt%) and large quantities of the harmful solvent 1,4-dioxane, and the yield was reduced by the formation of an oxime-ester byproduct. These issues were tackled by using 2-methyl THF as a substitute for dioxane and running the reaction at higher concentrations with only 20 wt% enzyme loading. The byproduct was successfully converted to the target product by addition of hydroxylamine. Crystallization from water yielded molnupiravir in high purity and 71 % yield.

The overall yield was improved from 37 % to 60 % and both reaction steps were successfully upscaled to a 0.5 kg scale. The synthesis route does not require chromatographic purification and uses environmentally benign solvents and cheap starting materials. Therefore, it could be suitable for the low-cost, large-scale production of molnupiravir.


 

Also of Interest

News: Coronavirus Drug Molnupiravir

  • 05 October 2021

Molnupiravir significantly reduces risk of hospitalization and/or death, according to Merck

thumbnail image: Coronavirus Drug Molnupiravir

News: Improved Synthesis Route for Molnupiravir

  • 04 August 2021

Efficient synthesis from cheap and easily available cytidine

thumbnail image: Improved Synthesis Route for Molnupiravir

Research Highlight: How Molnupiravir Causes SARS-CoV-2 to Mutate and Die

  • 07 September 2021
  • Author: Roswitha HarrerORCID iD

Mechanism might apply to various viral polymerases and could explain broad-spectrum antiviral activity of molnupiravir

thumbnail image: How Molnupiravir Causes SARS-CoV-2 to Mutate and Die

News: High-Yielding Synthesis of Antiviral Drug Candidate

  • 19 November 2020

Improved preparation of EIDD‐2801, currently in clinical trials for COVID-19 treatment

thumbnail image: High-Yielding Synthesis of Antiviral Drug Candidate

News: Oral Drug Blocks SARS-CoV-2 Transmission in Ferrets

  • 09 December 2020

Repurposed ribonucleoside analogue inhibitor of influenza viruses

thumbnail image: Oral Drug Blocks SARS-CoV-2 Transmission in Ferrets

 

 

 

Leave a Reply

Your email address will not be published.